Several CNS drugs have already been repurposed for non-CNS indications, e.g., thalidomide (sedative/hypnotic to multiple myeloma and leprosy), chlorpromazine (antihistaminic to anticancer - inhibitor of the mitotic kinesin KSP/Eg5)11, etc. Nonetheless, PK/PD, adverse reactions, toxicity and the clinical trials data obtained from the original drug may guide the design of such experiments for the non-CNS analogs. This evidence concerns the gene KIF11 and AL amyloidosis.